Targeting CDK4/6 in glioblastoma via in situ injection of a cellulose-based hydrogel

Abstract

Despite aggressive treatments, including surgery, chemo- and radio-therapy, the prognosis of glioblastoma (GBM) remains poor and tumor recurrence is inevitable. The FDA-approved CDK4/6 inhibitor palbociclib (PB) showed interesting anti-GBM effects,...

Investigation of sponge medium for efficient concurrent tumor treating fields and radiotherapy for glioblastomas

“…[6][7][8] With persistent efforts made in the past few years, several viable strategies, including tumor resection, radiotherapy, chemotherapy with temozolomide (TMZ), and immunotherapy, have been developed. [9][10][11] Despite some success, therapy efficacy is still challenging, and the associated adverse effects seriously impact the quality of patients' life. 12,13 Fortunately, TTFields provide a noninvasive method to cure GBMs through affixing transducer arrays on the scalp, which deliver a local low-intensity alternating current electric field (100-400 kHz) locoregionally around the anatomic region of the tumor and selectively disrupt cell division.…”

“…6–8 With persistent efforts made in the past few years, several viable strategies, including tumor resection, radiotherapy, chemotherapy with temozolomide (TMZ), and immunotherapy, have been developed. 9–11 Despite some success, therapy efficacy is still challenging, and the associated adverse effects seriously impact the quality of patients' life. 12,13…”